Pirtobrutinib is a non-covalent inhibitor. It targets the BTK, a protein vital for B cell signaling. It’s mainly used to treat mantle cell lymphoma and CLL.
The medication comes in two strengths: 50 mg and 100 mg tablets, with the recommended dose being 200 mg taken once daily. Each bottle has 60 tablets of that dose. The non-covalent part means it’s more of a temporary thing, like a handshake with the BTK enzyme.
It’s also said to be more targeted than the covalent ones.
Reviews
There are no reviews yet.